Insights

An interview with John Liu: From DIO (diet-induced obesity) Models to Patients: Accelerating the Next Generation of Obesity Drugs

GLP-1 drugs like semaglutide and tirzepatide have demonstrated significant weight loss and improved metabolic profiles. However, a major clinical challenge is weight rebound after treatment ends. Tria
September 19, 2025

Q&A:In Vitro Evaluation for STAT6 Degraders, Using Kymera's Patented Molecule as an Example

To uncover the story behind one of the most promising frontiers in immunology and drug discovery, we sat down with Lin Teng, PhD, head of Biology Department at BioDuro. Her team played a key role in developing and validating an advanced STAT6 PROTAC evaluation platform—accelerating the journey from patent to preclinical proof. Below is a brief Q&A that highlights some of the exciting developments and challenges in targeting STAT6 using PROTACs.
July 14, 2025

Solid-Phase or Liquid-Phase? How Has Peptide Synthesis Revolutionized Drug Discovery?

This article, with insights from Yuyan Chen, Director of Medicinal Chemistry, BioDuro, was originally published in the European Biopharmaceutical Review, Summer 2025,pages 54-56. Visit the websit
June 18, 2025

Solution Engine: Enhancing Bioavailability With Reliable In-Vivo/In-Vitro Data in 4–6 Weeks

Originally published in the Drug Development & Delivery June 2025 Issue: CDMOs & Supply Chains (Vol 25 No 4).
June 06, 2025

What are "3 Key Trends" shaping the CDMO industry in 2025 and beyond?

Originally featured in the Contract Pharma May 2025 roundtable discussion CDMOs: Key Leader Insights. Visit the Contract Pharma website: contractpharma.com
May 28, 2025

Interview with Dr. Armin Spura: BioDuro's Recent Investment and Expansion Plan

Watch the full video to learn how BioDuro is building the future of biopharma manufacturing—globally and with purpose.
April 30, 2025

Riding the Oral GLP-1 Wave: CDMOs and Orally Administered GLP-1s

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.
April 29, 2025

Building Strategic Partnerships Through Integrated CRDMO Services

Dr. Jim Li, President of CMC Solutions at BioDuro recently had the pleasure to sit down with the Pharma Source team to discuss how we build strategic partnerships through our integrated CRDMO Services.
April 18, 2025
Total 29 1234
✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all